With its next earnings report scheduled for around Aug. 10, Haemonetics stock is trading about 10% shy of a 75.44 buy point. The current formation is a first-stage consolidation.
Understand that it's risky to buy any stock just before it reports. You can reduce your exposure by waiting to see how the company reports and how the market reacts.
Looking For Winning Stocks? Try This Simple Routine
Earnings grew 41% last quarter, up from 4% in the prior report. Revenue also increased, from 8% to 18%.
Consensus analyst estimates call for earnings growth of 2% for the quarter, and a 6% gain for the full year.
Haemonetics stock has a 96 Composite Rating and holds the No. 2 rank among its peers in the Medical-Systems/Equipment industry group. Haemonetics is the top-ranked stock within the group.
Note: Dates for earnings reports are subject to change. Check the company's website for any updates.
